230 related articles for article (PubMed ID: 32760603)
21. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
Klemke CD; Booken N; Weiss C; Nicolay JP; Goerdt S; Felcht M; Géraud C; Kempf W; Assaf C; Ortonne N; Battistella M; Bagot M; Knobler R; Quaglino P; Arheiliger B; Santucci M; Jansen P; Vermeer MH; Willemze R
Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
[TBL] [Abstract][Full Text] [Related]
22. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.
Horna P; Moscinski LC; Sokol L; Shao H
Cytometry B Clin Cytom; 2019 May; 96(3):234-241. PubMed ID: 30328260
[TBL] [Abstract][Full Text] [Related]
23. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
24. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
Nikolova M; Bagot M; Boumsell L; Bensussan A
Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides.
Cetinözman F; Jansen PM; Vermeer MH; Willemze R
Arch Dermatol; 2012 Dec; 148(12):1379-85. PubMed ID: 23247480
[TBL] [Abstract][Full Text] [Related]
26. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
29. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma.
Cetinözman F; Jansen PM; Willemze R
Am J Surg Pathol; 2012 Jan; 36(1):109-16. PubMed ID: 21989349
[TBL] [Abstract][Full Text] [Related]
30. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
31. [Epidermotropic T cell lymphomas as models for tumor progression].
Bagot M; Bensussan A
Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
[TBL] [Abstract][Full Text] [Related]
32. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
[TBL] [Abstract][Full Text] [Related]
34. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma.
Vowels BR; Lessin SR; Cassin M; Jaworsky C; Benoit B; Wolfe JT; Rook AH
J Invest Dermatol; 1994 Nov; 103(5):669-73. PubMed ID: 7963654
[TBL] [Abstract][Full Text] [Related]
35. In vivo imaging of cutaneous T-cell lymphoma migration to the skin.
Hoeller C; Richardson SK; Ng LG; Valero T; Wysocka M; Rook AH; Weninger W
Cancer Res; 2009 Apr; 69(7):2704-8. PubMed ID: 19318575
[TBL] [Abstract][Full Text] [Related]
36. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
37. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
38. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma.
Bagot M; Echchakir H; Mami-Chouaib F; Delfau-Larue MH; Charue D; Bernheim A; Chouaib S; Boumsell L; Bensussan A
Blood; 1998 Jun; 91(11):4331-41. PubMed ID: 9596682
[TBL] [Abstract][Full Text] [Related]
39. Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4
de Freitas E Silva R; Gálvez RI; Pereira VRA; de Brito MEF; Choy SL; Lotter H; Bosurgi L; Jacobs T
Front Immunol; 2020; 11():574491. PubMed ID: 33193363
[TBL] [Abstract][Full Text] [Related]
40. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.
Yao H; Wang H; Li C; Fang JY; Xu J
Front Immunol; 2018; 9():1774. PubMed ID: 30105035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
